Form 4: Lixte Biotechnology Director Regina Brown Reports Stock Option Grant
SEC Form 4
Director Regina Brown reports the acquisition of stock options in Lixte Biotechnology Holdings, Inc. in lieu of quarterly cash compensation.
Summary
- Regina Brown, a director of Lixte Biotechnology Holdings, Inc., filed a Form 4 on October 28, 2024, reporting a transaction that occurred on September 30, 2024.
- Brown acquired options to purchase 6,269 shares of common stock at an exercise price of $1.30.
- These options were granted in lieu of quarterly cash compensation under the Board Compensation Plan and vested immediately.
- Brown also holds other options to purchase common stock at various exercise prices and expiration dates.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It's a routine disclosure of stock option grants to a director, which is a common practice.
Positives
- The grant of stock options to a director aligns their interests with those of shareholders.
- The immediate vesting of the options may incentivize the director to contribute to the company's success.
Industry Context
Form 4 filings are standard practice and provide transparency into the transactions of company insiders.
Stakeholder Impact
- The grant of stock options to a director can align their interests with those of shareholders, potentially leading to increased shareholder value.
Key Dates
| Date | Description |
|---|---|
| 05/11/2021 | Date of options grant with an exercise price of $28.00 and expiration date of 05/11/2026 for 25,000 shares. |
| 06/30/2021 | Date of options grant with an exercise price of $30.30 and expiration date of 06/30/2026 for 10,000 shares. |
| 06/30/2022 | Date of options grant with an exercise price of $7.45 and expiration date of 06/30/2027 for 10,000 shares. |
| 06/30/2023 | Date of options grant with an exercise price of $5.88 and expiration date of 06/30/2028 for 10,000 shares. |
| 06/30/2024 | Date of options grant with an exercise price of $2.37 and expiration date of 06/30/2029 for 14,904 shares. |
| 09/30/2024 | Date of transaction: Regina Brown acquired options to purchase 6,269 shares of common stock at $1.30. |
| 10/28/2024 | Date of Form 4 filing. |
Keywords
stock options, Form 4, director, Lixte Biotechnology, Regina Brown, beneficial ownership, compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.